Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | -0.01% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of LRMR is 14.3 and suggests 436% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre